ArticleJournal of ovarian research2026
Two-staged CT-based radiomics model in characterising early-stage ovarian carcinoma and benign ovarian masses.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCharacterisation of CT detected ovarian masses is challenging with overlapping imaging features, unreliable biomarker or clinical presentation. We proposed a two-staged CT-based radiomics model to identify early-stage ovarian carcinoma (ES-OC) and sub-classify different types of benign ovarian masses (BOM).
methodsPatients with histologically confirmed BOM or ES-OC (FIGO I-II) were retrospectively recruited from 5 centres. Radiomics features were derived from CT images using PyRadiomics (v3.0.1), which intrinsically resampled volumes to isotropic 1 mm³ voxels. To reduce feature redundancy, features with high correlation (Spearman's ρ ≥ 0.85) were excluded. Two-staged feature selection was applied. First, elastic-net regression with repeated 5-fold stratified cross-validation (100 iterations) was performed to identify highly repeatable features, followed by Mann-Whitney U testing for statistical significance. Second, Boruta algorithm with Random Forest (RF) estimator was employed over 500 iterations to robustly select features by comparing their importance to randomized shadow features. Several machine learning (ML) classifiers were evaluated using stratified 10‑fold GridSearch cross-validation with area under the curve (AUC) as tuning metric. The optimal model from each stage with highest cross-validated AUC was then evaluated on the respective test set. The AUC, calibration plot, and decision curve analysis (DCA) were employed to assess the performance and clinical utility of models.
resultsThe study enrolled 483 patients with 529 lesions (ES-OC: 192 patients, 192 lesions; BOM: 291 patients, 337 lesions). In the first-stage, logistic regression (LR) algorithm was selected with high sensitivity (0.870), moderate specificity (0.719) and high AUC (0.859) in the test set. In the second-stage, support vector machines (SVM) had high diagnostic accuracy with sensitivity 0.750, specificity 0.839 and AUC 0.918. DCA identified the highest benefit at 0.20 risk threshold probability in determining ES-OC.
conclusionThe two-staged CT-based radiomics model incorporating LR and SVM algorithms had high diagnostic efficiency in characterising ES-OC and BOM, potentially in triaging disease and personalising care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.